A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose

PURPOSE: To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), safety, pharmacokinetics, and pharmacodynamics of SB-743921 when administered as a 1-h infusion every 21 days to patients with advanced solid tumors or relapsed/refractory lymphoma. METHODS: Patients who failed pri...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Holen, Kyle D., Belani, Chandra P., Wilding, George, Ramalingam, Suresh, Volkman, Jennifer L., Ramanathan, Ramesh K., Vasist, Lakshmi S., Bowen, Carolyn J., Hodge, Jeffrey P., Dar, Mohammed M., Ho, Peter T. C.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2010
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4160065/
https://ncbi.nlm.nih.gov/pubmed/20461380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1346-5
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk